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INTRODUCTION
Short stature is one of the most common and 
most important diagnostic dilemmas in pediatric en-
docrinology. Besides the “normal” variants – famil-
ial short stature and constitutional delay of growth 
and puberty, the other causes include a variety of dif-
ferent endocrine and metabolic disorders, many syn-
dromes and chronic systemic illnesses as well as nu-
merous rare inborn genetic conditions (1). Among 
the last ones the skeletal dysplasias (osteochondro-
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dysplasias) comprise a unique group of more than 
450 congenital disorders that could lead to a diverse 
number of abnormalities of cartilage and bone devel-
opment (2). We present a boy with confirmed growth 
hormone (GH) deficiency with poor response to 
growth hormone treatment due to a coexisting mul-
tiple enchondromatosis (Ollier disease). Enchondro-
mas are characterized by the presence of ectopic be-
nign cartilaginous tumors incorporated within the 
different sites of the mineralized bone tissue. The 
disorder has several subtypes, no gender bias and can 
manifest at any age with the symptoms of pain, skel-
etal deformities, pathological fractures or dispropor-
tionate short stature (3,4).
Our patient: 
A 9-year-old boy presented at the clinic with 
pre- and postnatal growth retardation. He was born 
from second normal pregnancy of non-consanguin-
eous parents and was delivered 2 weeks before term 
small for gestational age, with mildly decreased birth 
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weight of 2200 g and length of 43 cm. There was no 
family history of growth failure or any other genet-
ic, endocrine or systemic disorders. At presentation, 
the general physical examination did not reveal any 
significant abnormalities or dysmorphic features, 
except of a triangular face with a slight asymmetry 
and a mild pigeon-shaped chest deformity. He had 
a proportional body appearance with a height of 104 
cm (18 cm below the 3th percentile, - 5.0 SDS) and 
weight of 13 kg (9 kg below 3th percentile, - 7.9 SDS). 
The standard laboratory blood tests were normal. 
The hormonal analyses showed thyroxine and cor-
tisol levels in the normal range (TSH 1.25 uIU/ml, 
FT4 16.4 pmol/l, cortisol 401.72 nmol/l), but the IGF-
1 (insulin-like growth factor-1) 52.4 µg/l was below 
the lower limit (N 74-388). In order to assess the po-
tential of growth hormone production from the pi-
tuitary, an insulin tolerance test and a glucagon test 
were performed showing a maximal peak of growth 
hormone 6.63 ng/ml (N > 10 ng/ml) – a result sug-
gestive of growth hormone deficiency. The patient’s 
bone age, estimated according to Greulich and Pyle 
method, was also decelerated with more than 4 
years, which was also consistent with the diagno-
sis of growth hormone deficit. There were no bone 
deformities on the wrists that were followed every 6 
months. Finally, after the MRI of the hypothalamus-
pituitary did not show any abnormalities or lesions, 
the child was started on growth hormone replace-
ment therapy with gradually increasing doses. 
Unfortunately, despite the excellent compliance 
by the family, during the next couple of years the 
child’s growth velocity did not improve while bone 
age was progressing and the boy did not manage to 
catch-up in height (Fig. 1). Instead of this, a progres-
sive development of an O-shaped deformity of his 
legs began to attract the attention. There was no pain 
or any other complaints. At the end of our follow-up 
of more than 3 years, the boy’s gait became waddling 
and his appearance more and more disproportion-
ate. At 12 years of age the intercondylar distance (the 
distance between the medial femoral condyles of his 
knees) was 10 cm (reference< 6 cm) (5). At the same 
time, his sitting height to height ratio became 0.55 
cm (> + 2.5 SD) and his lower segment to upper seg-
ment ratio was 1.22 - > + 2.5 SD (Fredriks et al, 2005). 
These measurements proved the presence of a signif-
icant disproportion with shortening of the leg length 
- a finding requiring further investigations (Fig. 2). 
In the region of both knees roentgenograms 
showed symmetrical and predominantly medial me-
taphyseal widening due to clusters of multiple, ra-
diolucent, homogenous enchodromatous lesions and 
formation of genua vara. Multiple strip-like longitu-
dinal small foci of osteosclerosis were visualized. The 
metaphyses’ outline was not clear-cut. Similar chang-
es were found in the iliac bones too, but the arms, the 
hands, the skull and the vertebral bodies were unaf-
fected (Fig. 3-5). There were pseudo epiphyses at the 
basis of the second metacarpal bones bilaterally. The 
co-presence of multiple enchondromatosis or Ollier 
disease was diagnosed. 
DISCUSSION
Benign cartilaginous tumors can grow inside 
the bone as endosteal tumors – enchondromas or as 
osteochodromas (exostoses) that grow on bone sur-
face. They are a result from different types of dereg-
ulation of the normal chondrogenesis and bone for-
mation (3,4). The main skeletal growth instrumen-
tality is the endochondral bone ossification that takes 
Fig. 1. Patient‘s growth chart
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place in the growing parts of the long tubular bones 
(growth plates) where undifferentiated mesenchymal 
cells undergo several stages of transformation form-
ing the zones of the resting, proliferating and hy-
pertrophic chondroid cells. The bone elongation is 
mainly achieved by the work of the actively prolif-
erating chondrocytes which finally exit the cell cycle 
and differentiate into non-dividing terminal hyper-
trophic cells. The increasing volume of the last ones 
also contributes significantly to the skeletal growth. 
Fig. 3. Unaffected hands and wrists with 
pseudoephiphyses (II, V metacarpals) and deceleration in 
bone maturity
Fig. 4. Multiple enchondromatous lesions in the 
metaphyseal regions of both knees
Fig. 5. Enchondromatous changes in iliac bones
Fig. 2. The patient at the time of making the current 
diagnosis
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Ultimately, the hypertrophic chondrocytes calcify 
their surrounding extracellular matrix and undergo 
apoptosis thus becoming a part of the mineralized 
template that serves as a scaffold for the subsequent 
bone formation by the invading osteoblasts (3,4).
The growth and the differentiation of the car-
tilaginous cells in the epiphyseal growth plates are 
tightly regulated by multiple endocrine, paracrine 
and local signaling molecules including bone-mor-
phogenic proteins (BMPs), tumor-growth factor beta 
(TGFβ), insulin-like growth factor-1 (IGF-1), indian 
hedgehog (IHH), thyroid and sex hormones, para-
thyroid hormone-related peptide (PTHrP) and Wnt/
β-catenin pathway (3,4).  
Enchondromas themselves are a heterogeneous 
group of non-hereditary, sporadic skeletal disorders 
characterized by the presence of hyaline cartilage tu-
mors located nearby the growing parts of the affect-
ed bones. Usually enchondromas are solitary, benign 
and asymptomatic. On x-rays they present as lin-
ear or oval-shaped intraosseous osteolytic loci with 
well-defined borders. Sometimes a light trabecula-
tion may be also visible. Although the typical loca-
tion is the medulla of the long tubular bones, espe-
cially the metaphyseal zones, flat bones could be also 
involved. Histologically the lesions show abundant 
hyaline cartilage matrix with low cellularity, often 
with zones of calcification. Initially the enchondro-
mas appear close to the growth plate cartilage where 
the endochondral bone ossification takes place and 
then migrate towards the diaphysis (4,6).
When multiple, the lesions are generally de-
fined as Enchondromatosis that encompasses sever-
al different subtypes of which Ollier disease, Maffu-
ci syndrome and metachondromatosis are the most 
common ones.
First described in 1889, Ollier disease (OMIM 
166000) is the most common subtype with estimated 
prevalence of 1/100 000 (7). It is a non-familial dis-
order with only a few familial cases that have been 
reported. The diagnosis is mostly encountered in 
childhood and both sexes are equally affected. The 
clinical manifestation often appears during the first 
decade of life and entirely depends on the size, num-
ber and location of the tumors. The typical evolu-
tion leads to the development of bone deformities, 
limb shortening with or without pathological frac-
tures. Lesions are often asymmetrically distributed 
and may involve any part of the skeleton, although 
the vertebral bodies and the skull are very rarely af-
fected. Because of the irregular distribution of the le-
sions, it is widely accepted that the abnormalities of 
the bone formation might be a result of a post-zygotic 
somatic mutations that lead to mosaicism (4,6,7). In 
small percentage of the patients, a mutation is found 
in the gene for PTH1R, the receptor for parathyroid 
hormone-related peptide (PTHrP) – one of the key 
signaling molecules that control the normal chon-
drocyte differentiation in the growth plates (8).
The presence of enchondromas in association 
with soft-tissue cavernous haemangiomas is termed 
Maffuci syndrome, OMIM 614569. In these cases the 
lesions are typically located in the hands and feet (6,9).
The malignant transformation towards second-
ary central chondrosarcoma is the major complica-
tion and can occur in up to 30-40% of the patients 
with Ollier disease and even higher for patients with 
Maffucci syndrome. More interestingly, non-skeletal 
tumors – gliomas, acute myeloid leucemia, abdomi-
nal tumors, have also been occasionally reported (4, 
10). Recent genetic studies discovered that up to ap-
proximately 80% of patients with Ollier disease and 
Maffucci syndrome carry in their tumors a somatic 
mutation in isocitrate dehydrogenase gene-1 (IHD-1) 
and IHD-2. The mutations in both genes result in a 
defect of the metabolism of α-ketoglutarate with the 
overproduction of molecules with oncogenic poten-
tial like 2-hydroxyglutarate that can change the his-
tone methylation and the expression of several onco-
genes (10,12). 
Metachondromatosis, OMIM 156250, the third 
major form of enchondromatosis, is characterized by 
the combination of enchondromas and osteochon-
dromas. Although only about 30 cases have been re-
ported, it is clear that the disease shows an autosomal 
dominant pattern of inheritance. In 2010 Sobreira 
and in 2011 Bowen discovered that loss-of-func-
tion mutations in PTPN11 gene (12q24) are linked 
to the disease. PTPN11 gene encodes a protein tyro-
sine phosphatase SHP2 that is involved in a variety of 
signaling pathways. According to the data from re-
cent mice models studies, SHP2 seems to play an im-
portant role in cartilage development and SHP2-de-
ficient mice show delayed terminal differentiation of 
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the hypertrophic chondrocytes and ectopic chondro-
genesis (6,13).
Hereditary multiple osteochondromatosis is an-
other form of generalized exostosis which is caused 
by mutations in EXT1 (8q24.1) and EXT2 (11p13) 
genes. Approximately in 60% of the cases the disease 
is inherited from one of the parents and in the rest of 
the patients it is due to a de novo mutation. Both EXT 
genes encode transmembrane glycosyltransferases – 
exostosin-1 and exostosin-2, involved in the produc-
tion of heparin sulfate (14).
To the best of our knowledge, there is no 
published case in the literature with the combined 
presence of Ollier disease and growth hormone 
deficiency. The bone disease diagnosis poses the 
question whether the GH treatment should be 
stopped, especially in the view of the increased 
malignancy risk in such patients. Since there is no 
guidance in the literature, our current decision is to 
stop for 6 months and re-test for GH deficiency and 
possible sequels of its shortage (lipid metabolism, 
muscle tonus, etc.). The final decision whether to 
continue or not with the GH treatment will be then 
discussed extensively with the family.
CONCLUSIONS
We present a rare case of short stature due to the 
combination of isolated growth hormone deficiency 
and a rare type of underlying osteochodrodysplasia. 
The poor response to growth hormone treatment and 
the risk of developing malignant transformation in 
the future raises the important questions of the real 
benefits and the possible harms of the maintenance 
of such a therapy. 
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